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1. Introduction 
The notion of replacing brain cells affected by a particular disease or unable to synthesize a 
molecule crucial for adequate brain function has been around for many years.  The first 
experiments entailed the transplantation of adult tissue into an adult or young animal; they 
were met with limited success (Björklund & Stenevi, 1984).  Later, scientists started working 
with fetal tissue, because this tissue fares better when dissected, axons are shorter, cells are 
still dividing, and growth factors are present in the tissue.  These studies were more 
successful and led to clinical trials using human fetal tissue, and autologous transplants of 
adrenal chromaffin cells, especially for Parkinson´s disease (Freed, 1991).  Transplants were 
first used in this neurodegenerative disorder because it was assumed that the main problem 
was the lack of dopamine in the striatum, and this neurotransmitter could be readily 
provided by chromaffin cells from the adrenal medulla or by mesencephalic dopaminergic 
cells.  Initial preclinical studies had shown, using the 6-OHDA model developed by 
Ungerstedt (Ungerstedt 1968; Ungerstedt & Arbuthnott, 1970), that intrastriatal grafts of 
mesencephalic cells could reduce the number of ipsilateral or contralateral rotations induced 
by apomorphine or amphetamine, suggesting that the dopaminergic tone had been restored 
in the lesioned striatum. These studies led to others using fimbria fornix lesions (e.g., 
Dunnett et al., 1982), diabetes insipidus model (e.g., Gash & Sladek, 1980), Huntington´s 
disease models (e.g., Norman et al., 1989), and epilepsy models (e.g., Castillo et al., 2006).  In 
addition to the experiments showing functional effects of the transplants, there were others 
looking for the mechanisms underlying the effects of the transplans. A series of studies 
showed that transplanted cells could establish reciprocal anatomical connections with the 
host (Wictorin, 1992; Murata et al., 1990).  A couple of studies using electrophysiology, and 
markers or cell activation showed that these connections were functional (Xu et al., 1991; 
Rutherford et al., 1987; Labandeira-Garcia & Guerra, 1994).  Neuroscientists involved in this 
field concluded that neural transplants could affect the host brain by releasing growth 
factors, and neurotransmitters, and by establishing functional connections with the host 
brain, thus reestablishing lost circuits. 
However, the source of tissue for transplantation was still an issue to be considered.  Fetal 
tissue was not readily available in all countries, and its use implicated ethical and legal 
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issues not easily resolved.  In addition, fetal tissue included all kinds of cells, and in spite of 
the immuno-privileged status of the brain, it could lead to an inflammatory response in the 
host.  Autologous transplants of chromaffin cells (Freed et al., 1990) and xeno-transplants 
(Fink et al. 2000) had been used as an alternative source of  tissue for transplantation.  Then, 
with the advent of new molecular biology techniques, cell lines with particular properties 
and characteristics were developed.  GABAergic cell lines proved easier to develop than 
dopaminergic cell lines, and given the fact that epilepsy has been considered as a disorder in 
which there is an imbalance between excitation and inhibition, these cell lines started to be 
tested in epilepsy animal models.  More recently, once it was demonstrated that Cajal’s 
notion that in the adult nervous system neurons no longer divide was incorrect, and that 
there are neurogenic pools in the adult brain (Nottebohm, 2002), the potential use of these 
immature cells for transplantation became a possibility.  Furthermore, a myriad of studies 
started looking for factors to differentiate these immature nerve cells into the desired type of 
nerve cell, dopaminergic, cholinergic, GABAergic, among others (Vazin & Freed, 2010; 
Mejía-Toiber et al., in press).  Cell lines could be developed from these adult but immature 
cells, thus solving the problem of having a source of tissue for transplantation.  Moreover, 
now we know that cells, such as fibroblasts can be reprogrammed into neuronal cells (e.g., 
Takahashi & Yamanaka, 2006), thus, in theory the host could eventually replace its own 
damaged cells.  In this brief overview of the field of neural transplantation, we have seen 
how the sources of tissue for transplantation have expanded, the techniques have been 
refined, and new possibilities have emerged to try and restore function in the nervous 
system.  Still, questions remain, how is it that the new cells can modify the function of the 
host nervous system, is it the transplant that changes the host brain and takes some of its 
functions, or is it the host brain itself that is modified as a result of the presence of the alien 
cells in its midst.  Is it necessary to transplant new cells into the brain, or do we have to learn 
how to activate the neurogenesis that is already taking place in the adult brain.  How can 
cells be differentiated without posing a risk for the host, which plasmids are safe to us, and 
which are not. In the following sections we will focus on the advances of neural transplants 
in animal models of epilepsy, and in the clinical setting in Parkinson’s disease. 
2. Preclinical studies using cell transplants of fetal tissue and neural stem 
cells in animal models of epilepsy 
Epilepsy is a neurological disorder with a prevalence of about 1% (Morimoto, Fahnestock 
et al. 2004) characterized by seizures that occur in a spontaneous and recurrent manner. 
Seizures are classified as generalized and can manifest themselves as uncontrolled 
muscular activity or as a sudden interruption of physical and mental activity (absence 
seizures); or as focal seizures, that are classified according to their manifestation, i.e., if 
they involve psychic or sensory phenomena, motor or autonomic components, loss of 
awareness, or evolving to a bilateral, convulsive seizure (Berg et al., 2010). Epileptic 
seizures are the result of abnormal, excessive and synchronic discharges of groups of 
neurons that occur as a result of changes in synaptic function and intrinsic properties of 
neurons that upset the balance between inhibitory and excitatory neurotransmission, 
favoring the latter (Cossart et al., 2001). In the recent document published by the 
International League Against Epilepsy (ILAE) Commission on Classification and 
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Terminology (Berg et al., 2010), the underlying type of causes of epilepsy are considered to 
be genetic, structural-metabolic or unknown.  
Epilepsy is one of the neurological disorders that could benefit from transplantation of cells, 
since some types of epilepsy are focal, and in the case of generalized seizures they can be 
suppressed by local injections of GABAergic agents into particular areas of the brain such as 
the substantia nigra, or piriform cortex (Gale, 1992). Indeed, Kokaia et al. (1994) observed a 
reduction in generalized seizures in rats previously kindled in the amygdala when GABA-
releasing polymer matrices were implanted bilaterally and dorsal to the substantia nigra.  
The effect lasted until GABA release from the polymer matrices was reduced. Thus, local 
delivery of an inhibitory neurotransmitter could reduce the neuronal excitability in brain 
regions from which seizures originate or in brain regions from which they propagate to the 
rest of the brain.  
Initially, studies using transplants in epilepsy models used fetal tissue with some success.  
Barry et al., (1987) (Table 1), evaluated the effect of fetal noradrenergic transplants in the 
hippocampus using the kindling model of epilepsy.  This model consists in the use of 
repeated subthreshold electrical stimulations of specific regions of the Central Nervous 
System (CNS). Afterwards, the animal presents focal epileptiform seizures that then 
generalize to the rest of the brain.  The work of Barry et al. (1989) involved first, the 
administration of 6-hydroxydopamine (6-OHDA) icv, and then the transplant of fetal 
noradrenergic cells into the hippocampus.  The authors of the study found that animals 
required a greater number of stimulations to induce the various phases of kindling, in 
comparison with rats that did not receive the transplants.  Also the delay in kindling was 
related to the density of innervation of the transplant in the host hippocampus.  They 
obtained similar results when transplanting cells of the locus coeruleus into the amygdala 
and piriform cortex (1989) (see Table 1).  A study using noradrenergic cells obtained from 
locus coeruleus (LC) from E13-E14 rats showed that these cells could reinstate noradrenergic 
transmission in the noradrenaline-depleted hippocampus (Bengzon et al., 1991).  In this 
particular study, they measured noradrenaline-release using microdialysis after electrical 
stimulation of the hippocampus, and observed that noradrenaline release from intrinsic and 
grafted LC neurons occurred concurrently with their seizure suppressing action; thus LC 
grafts in the hippocampus appeared to be functionally integrated into the host brain, at least 
during generalized kindled seizures (Bengzon et al., 1991).  
Fetal GABAergic cells have also been used with varying degrees of success in other epilepsy 
models.  Fine et al. (1990) used the pilocarpine model in rats with ibotenic acid striatal 
lesions. Fetal GABAergic cells from the ganglionic eminence (E16) were transplanted into 
the substantia nigra pars reticulata (SNr), and suppressed the motor seizures; however, 
similar effects were observed after sciatic nerve transplants, suggesting a non-specific effect. 
Almost a decade later, Löscher et al., (1998) implanted fetal striatal GABAergic neurons into 
the substantia nigra in fully kindled animals, and evaluated the threshold for focal 
discharges (ADT), afterdischarge duration and severity, and duration of seizures during 
ADT.  They found a significant increase in ADT and marked reduction in seizure severity 
compared with pre-transplantation values; however, the seizure-suppressing effect of 
GABAergic grafts was not permanent but slowly disappeared over the weeks after 
transplantation (Löscher et al., 1998). 
Another decade later, better results were obtained by Rao et al., (2007) and Hattiangady et 
al., (2008) when these groups evaluated the effects of transplants of hippocampal cells 
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(E19), and lateral ganglionic eminence (E15) into the hippocampus in a model of 
spontaneous recurrent motor seizures (SRMS), respectively. Rao et al., (2007) pretreated 
the cells with brain derived neurotrophic factor, and neurotrophin-3, plus a caspase 
inhibitor, or with fibroblast growth factor (FGF-2). They observed that hippocampal cells 
not treated with trophic factors failed to reduce the SMRS, in contrast to those treated 
with the trophic factors and the caspase inhibitor; greater survival was observed with 
FGF-2. Hattiangady et al., (2008) pretreated precursor cells with FGF-2 and a caspase 
inhibitor, and found an important reduction in SRMS induced by kainic acid.  In addition 
they found that 69% of surviving transplanted neurons differentiated into GABAergic 
cells suggesting that the reduction in seizures is related with increased inhibitory control 
in the hippocampus.  
Stem cells with their properties of self-renewal and multipotentiality (Wang et al., 2007) 
represent another source for transplantation into the nervous system.  Pluripotent stem cells 
(PSC) can generate cells from all three embryonic germ layers, mesoderm, endoderm and 
ectoderm.  Two types of mammalian PSC have been identified, the embryonic stem (ES) cells 
derived from the inner cell mass of the blastocyst, and embryonic germ (EG) cells obtained 
from post-implantation embryos (Yu & Thomson, 2008).  Recent studies have identified 
different means of obtaining desired lineages from these human ES, for example neural stem 
cells (NSC) (Carpenter et al., 2001; Reubinoff et al., 2001; Zhang et al., 2001), further 
differentiated into midbrain dopaminergic neurons (e.g. Perrier et al., 2004), neural crest 
lineages (Lee et al., 2010), and neural progenitor cells from human EG cells (Pan et al., 2005).  
Various groups have also described differentiation of mouse stem cells into neural precursors, 
(e.g. Westmoreland et al., 2001; Kim et al., 2002; Barberi et al., 2003; Lang et al., 2004), and 
found positive functional effects after transplantation (Rodriguez-Gomez et al., 2007). 
In terms of their potential use in epilepsy models, it has been shown that NSC derived from 
the medial ganglionic eminence and transplanted in the hippocampus of adult rats showing 
spontaneous recurrent motor seizures, reduced motor seizures, but did not restore cognitive 
impairments (Waldau et al., 2010).  The NSC differentiated mostly into astrocytes, neurons, 
and oligodendrocyte progenitors.  About 50% or the cells expressed GDNF and 10% 
expressed GABA.  NSC grafts restored GDNF expression in hippocampal astrocytes.  The 
authors of the study suggest that the addition of new GABA neurons plus GDNF positive 
cells may underlie the therapeutic effects they observed.   
A different group has developed adenosine-releasing ES cells, by disruption of both 
alleles of adenosine kinase (Adk) which phosphorylates adenosine in eukaryotes and 
catalyzes the reaction: Adenosine + ATP= ADP + AMP. The cells were encapsulated in 
semipermeable polymer membranes and implanted into the lateral ventricles of kindled 
rats (Güttinger et al., 2005). The authors observed transient protection from convulsive 
seizures and a profound reduction of afterdischarge activity in EEG recordings. However, 
they suggest that long-term seizure suppression was precluded by limited viability of the 
encapsulated cells (Güttinger et al., 2005).   In a more recent study with male Sprague-
Dawley rats (Li et al, 2007) the same group derived NSC from Adk-/- or Adk+/+ ES cells.  
They implanted them into the hippocampus before kindling, and compared Adk-/- cells to 
adenosine releasing baby hamster kidney cells Adk-/- (BHK-AK2), and to wild type NSC.  
They observed that wild type NSC delayed the development of seizures; BHK-AK2 
exerted a moderate protection, whereas Adk-/-NSC retarded epileptogenesis during 
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kindling development and prevented the occurrence of generalized seizures.  The effect 
was sustained for 3 weeks; 26 days after grafting, histological analysis revealed dense 
cellular transplants in the vicinity of the injection tract, with 56% expressing mature 
neuronal markers (NeuN). 
NSC engineered to express enhanced green fluorescent protein under the control of the 
tau promoter were transplanted one month after pilocarpine treatment in the 
hippocampus of   Wistar male rats (Rüschenschmidt et al., 2005).  Electrophysiological 
recordings 13-34 days after transplantation showed that the NSC developed characteristic 
intrinsic and synaptic neuronal properties, and received excitatory and inhibitory 
synaptic inputs; there was no evidence of tumor formation.  Jing et al. (2009) described the 
transplantation into the hippocampus one-week after kainic acid-induced status 
epilepticus (SE) of NSC obtained from the subventricular zone of green fluorescent 
protein-expressing Sprague Dawley rats.  In this study an infusion of erythropoietin was 
delivered by means of an osmotic pump into the right lateral ventricle.  Erythropoietin 
(EPO) is a glycoprotein produced primary in the kidney but also produced locally in 
neural tissues, according to the authors it has shown neuroprotective effects in nervous 
system disorders including during the process of SE.  The results of this study indicated 
that NSC transplants were able to prevent the development of SRMS through the 
suppression of aberrant mossy fiber sprouting and by increasing the number of inhibitory 
neurons. EPO infusion increased survival but not differentiation or migration of NSC; in 
terms of effects on EEG, no differences were observed between NSC + EPO, and NSC + 
vehicle groups.   
Human NSC have also been used in models of SE.  Chu et al (2004) obtained human NSC 
from the ventricular zone of embryonic brain (15-weeks gestation); one of the clones 
obtained was infected with a retroviral vector encoding β-galactosidase (β-gal) and 
puromycin-resistant genes.  These cells were injected intravenously in a tail vein of male 
Sprague-Dawley rats, 24-h after pilocarpine-induced SE; the control group received only 
vehicle.  Six weeks later histological analysis or electrophysiological recordings of 
hippocampal slices took place. In the transplanted group the authors observed a reduction 
of convulsive seizures; β-gal+ cells were found in the hippocampal area (CA1, subiculum, 
hilus of the dentate gyrus, CA3), amygdala, and piriform cortex; in kidney, lungs, and 
spleen, without evidence of tumor formation.    In rats without SE, no cells were found in 
the brain. Cells were mostly GABA+ and parvalbumin+; field excitatory postsynaptic 
potentials in CA1 induced by stimulation of Schaffer collaterals were smaller in 
transplanted animals.  The authors concluded that intravenously transplanted human 
NSC suppress spontaneous recurrent seizures.  Using the same model Costa-Ferro et al. 
(2010) evaluated the therapeutic potential of bone marrow mononuclear cells (BMC) 
obtained from transgenic mice. BMC cells have been reported to stimulate endogenous 
glial or neural stem cells, reduce neuronal apoptosis and neurodegeneration, modulate 
inflammatory responses, release trophic factors and cytokines involved in tissue repair 
and regeneration, and promote self-repair mechanisms in the brain (Costa-Ferro et al., 
2010). Ninety-min after pilorcarpine-induced SE the animals received BMC or saline only 
via the tail-vain.  By 15 days after transplantation, none of the BMC transplanted animals 
showed SRMS, while all saline-treated animals did; 120 days later only 25% of 
transplanted animals showed SRMS with a lower frequency and duration than control 
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animals.  Transplants attenuated cell loss in the hippocampus and BMC were found 
distributed in the brain of pilocarpine-treated recipient animals.  In addition, long-term 
potentiation was preserved in the transplanted animals compared to pilocarpine-treated 
non-transplanted animals. The authors suggested that BMC could prevent the 
development of chronic seizures, reduce neuronal loss, and influence the reorganization 
of the hippocampal network. 
Maisano et al., (2009) have also used ES-derived NSC in animal models of epilepsy, and 
have transplanted the YC5 mouse ES line into the CA3 region of the hippocampus one week 
after kainic acid or pilocarpine administration.  The NSC expressed immature stem cell 
markers shortly after transplantation; with longer survival time (4-8 weeks) cells in the 
kainic acid model some cells expressed an early marker of granule neurons (Prox1). Eight 
weeks after transplantation many grafted neurons received synaptophysin-positive synaptic 
terminals, suggesting their integration into the host hippocampus.  The same group used 
human NSC and observed similar results after transplantation into the kainate-lesioned 
brain (In: Maisano, et al., 2009).  The cells migrated to the upper blade of the dentate gyrus 
only in mice that had experienced seizures, and expressed neuroblast markers 
(doubleclecortin, PSA-NCAM).  Mouse but not human NSC formed tetrocarcinomas when 
transplanted into the mouse hippocampus.  More recently, the same group has made 
electrophysiological recordings one month after transplantation into the dentate gyrus in 
kainate-treated mice.  Their results showed that the cells have normal electrophysiological 
properties, receive syaptic inputs, and have the ability to fire spontaneous potentials.  In 
their 2009 paper, Maisano et al. suggest the use of protocols to enrich for GABAergic 
precursors, based on the expression of glutamic-acid decarboxylase-67 (GAD67); they 
suggest the use of conditioned media, gene transfection of transcriptional factors, or 
sequential treatment with growth factors and molecules to guide progenitor cells toward 
GABAergic lineages.  
In a recent critical review (Shetty & Hattiangady, 2007) the authors state that there is no 
evidence in support of using stem cells in the treatment of temporal lobe epilepsy yet, 
although they acknowledge that the field is still in its initial stage of development.  This 
conclusion is still valid at present.  Among the strategies that Shetty and Hattiangady (2007) 
suggest for further advance in the field, two of them are particularly relevant for theme of 
the present review.  First, is the need for rigorous analyses of the efficacy of grafts of ES cells 
or NSC placed into the hippocampus after the onset of chronic epilepsy for suppressing 
seizures as well as learning and memory deficits. In particular, the question of the duration 
of the suppressive effects is particularly relevant, because as can be gathered from the 
evidence presented above, the grafts of either fetal tissue or NSC have been evaluated for 
relatively short periods. These analyses should include evidence for the long-term survival 
of the grafts, and the differentiation of the cells in these grafts into functional principal 
hippocampal neurons, or GABA-ergic interneurons.  Second, is the need for evaluating 
combination therapy, i.e., NSC or ES cells transplants and delivery of anticonvulsant 
compounds into the hippocampus during chronic epilepsy.  As these authors suggest, this 
strategy might result in significant seizure suppressing effects.  Finally, it should be 
emphasized that studies using fetal tissue and NSC transplants must include adequate 
control groups so that the effects of the grafts can be unequivocally attributed to the 
particular cell type or compound being tested. 
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Cell type 
 
Model 
Site of 
transplant 
Behavioral effects
Histological 
findings 
Reference 
Noradrenergic 
(locus coeruleus, 
E13-14) 
NA-depleted 
rats; kindling 6-
11 months after 
transplant. 
Hippocampus Delayed onset and 
retarded 
progression of 
kindling; 
correlated with 
neuron survival 
Barry et al., 1987 
Noradrenergic 
(locus coeruleus, 
E13-14) 
NA-depleted 
rats; kindling 2-3 
months after 
transplant. 
Amygdala-
pririform  
cortex 
Delayed onset and 
retarded 
progression of 
kindling. 
Barry et al., 1989 
Noradrenergic 
(locus coeruleus, 
E13-14) 
NA-depleted 
rats; kindling 3 
months after 
transplant, then 
midrodialysis. 
Hippocampus Retarded 
progression of 
kindling; restored 
basal and seizure-
induced 
extracellular 
noradrenaline 
levels in 
hippocampus, 
cells 
immunopositive 
for tyrosine 
hydroxylase. 
Bengzon et al., 
1991 
GABAergic 
(ganglionic 
eminence, E16) 
Ibotenic acid 
lesioned 
animals; 
pilocarpine 
administration 1 
month after 
transplant. 
Substantia  
nigra reticulata
Reduced 
occurrence of 
motor limbic 
seizures, and 
intensity score; 
grafts localized in 
the substantia 
nigra. 
Fine et al., 1990 
GABAergic 
(ganglionic 
eminence E14) 
Transplanted 
after fully 
kindled. 
Substantia  
nigra reticulata
Increased 
afterdischarge 
threshold, 
decreased 
severity; short-
lasting effects. 
Löscher et al., 
1998 
GABAergic 
(lateral 
ganglionic 
eminence, E15) 
KA-induced SE; 
transplanted 4 
days after SE ; 
evaluated 9-12 
months after SE.
Hippocampus Reduced number 
of SRMS; 
differentiated into 
GABAergic cells. 
Hattiangady et 
al., 2008 
Table 1. Studies using transplants of fetal tissue and neural stem cells into the brain in 
animal epilepsy models. 
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Cell type 
 
Model 
Site of 
transplant 
Behavioral effects 
Histological 
findings 
Reference 
Hipocampal 
cells (E19) 
KA-induced SE; 
transplanted after 
showing 
spontaneous motor 
seizures; evaluated 
2 monts after 
grafting. 
Hippocampus Reduced number of 
SRMS; greater 
survival of neurons 
and GABA 
interneurons in 
hippocampi if 
pretreated with 
neurotrophic 
factors and caspase 
inhibitor. 
Rao et al., 2007 
Neural stem 
cells (medial 
ganglionic 
eminence, 
E14) 
KA-induced SE; 
transplanted after 
showing 
spontaneous motor 
seizures; evaluated 
3 months after 
grafting. 
Evaluation of 
seizures and 
learning and 
memory. 
Hippocampus Reduced frequency 
and duration of 
SRMS; no 
improvement in 
cognitive function; 
differentiation into 
neurons (some 
GABA+), astrocytes 
and 
oligodendrocyte 
progenitors, 
restored GDNF in 
hippocampus. 
Waldau et al., 
2010 
Adenosine-
releasing ES 
cells 
encapsulated 
in polymer 
membranes 
Kindling model, 
evaluated 3 days 
after grafting until 
7 days. 
Lateral 
ventricle 
Transient 
protection from 
convulsive seizures 
and reduction of 
afterdischarge 
activity in EEG 
recordings. 
Güttinger et al., 
2005 
NSC from 
Adk-/- or 
Adk+/+ 
Kindling model, 
grafted before 
kindling; evaluated 
for 3 weeks. 
Hippocampus NSC from Adk-/- 
retarded 
epileptogenesis, 
prevented 
occurrence of 
generalized 
seizures. Dense 
cellular transplants, 
some cells NeuN+. 
Li et al., 2007 
Table 1. Studies using transplants of fetal tissue and neural stem cells into the brain in 
animal epilepsy models. (continuation) 
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Cell type 
 
Model 
Site of 
transplant 
Behavioral effects 
Histological 
findings 
Reference 
NSC  Pilocarpine 
treatment, 
transplanted one 
month later, 
evaluated 13-34 
days after 
transplantation. 
Hippocampus NSC showed 
intrinsic and 
synaptic neuronal 
properties, receive 
excitatory and 
inhibitory inputs. 
Rüschenschmidt 
et al., 2005 
NSC KA-induced SE, 
transplanted one 
week later, EEG 
recorded 3 weeks 
after 
transplantation. 
Hippocampus, 
with or 
without EPO 
(icv) 
Reduced frequency 
of abnormal spikes; 
attenuates aberrant 
mossy fiber 
sprouting; 
differentiated into 
GFAP+ astrocytes;  
EPO enhanced 
survival. 
Jing et al., 2009 
hNSC Pilocarpine-
induced SE, 24h 
later cells injected; 6 
weeks later, 
histology or 
electrophysiological 
recordings of 
hippocampal slices.
Intravenous 
administration, 
tail vein 
Reduction in 
convulsive seizures; 
smaller fEPSP in 
CA1; labelled cells 
found in 
hippocampus and 
other brain areas, no 
tumor formation. 
Chu et al., 2004 
BMC Pilocarpine-
induced SE, 90 min 
later cells injected; 
evaluated 15 and 
120 days later. 
Intravenous 
administration, 
tail vein 
Short-term 
suppressed SRMS; 
long-term only 25% 
animals with BMC 
showed SRMS of 
lower frequency and 
duration than 
controls; attenuated 
cell loss in the 
hippocampus; long-
term potentiation 
preserved. 
Costa-Ferro  
et al., 2010 
Table 1. Studies using transplants of fetal tissue and neural stem cells into the brain in 
animal epilepsy models.(continuation) 
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Cell type 
 
Model 
Site of 
transplant 
Behavioral effects 
Histological 
findings 
Reference 
NSC and 
hNSC 
KA or pilocarpine 
administration, 
transplanted one 
week later. 
Hippocampus 
CA3 
Expression of 
immature cell 
makers, and of 
granule cells after 
longer survival 
times. Inputs of 
synaptohpysin+ 
synaptic terminals. 
Mouse NSC formed 
teratomas. hNSC 
migrated to dentate 
gyrus. Neuronal 
electrophysiological 
characteristics. 
Maisano et al., 
2009 
Table 1. Studies using transplants of fetal tissue and neural stem cells into the brain in 
animal epilepsy models. (continuation) 
Adk: adenosine kinase, enzyme that phosphorylates adenosine in eukaryotes; BMC: bone 
marrow mononuclear cells; CA: Cornu Ammonis; EEG: electroencephalogram; EPO: 
erythropoietin; ES: embryonic stem cells; fEPSP: field excitatory postsynaptic potentials; 
GABA: gamma-aminobutyric acid; GDNF: glial–derived neurotrophic factor; GFAP: glial 
fibrillary acidic protein; hNSC: human neural stem cells; icv: intracerebroventricular 
administration; KA: kainic acid; NA: noradrenaline; NeuN: a mature neuronal marker; NSC: 
neural stem cells; SE: status epilepticus; SRMS: spontaneous recurrent motor seizures. 
3. Preclinical studies using cell transplants of cell lines in animal models of 
epilepsy 
The use of fetal tissue for transplantation involves ethical and technical issues that can be 
circumvented by using cell lines.  The advances in molecular biology techniques provided 
the means to immortalize and genetically modifiy cells to produce specific growth factors, 
and enzymes.  One example of a cell line with intrinsic GABAergic properties is the clone 
M213-20, derived from the ganglionic eminence of E14-15 Sprague-Dawley rats.  This cell 
line was obtained by immortalizing neuroblasts using the temperature sensitive allele (A58) 
of the SV40 large T antigen, and was found to have some GABAergic characteristics 
(Giordano et al., 1993; 1996).  This cell line was further modified by transfection with the 
hGAD67 cDNA by means of a plasmid based on the Epstein-Barr virus.  From the clones 
obtained, one was selected, the M213-2O CL-4 that synthesizes and releases significantly 
more GABA than the parent cell line (Conejero-Goldberg et al., 2000), reuptakes GABA, 
responds to glutamate, presents calcium transients, and releases the neurotransmitter in a 
calcium-dependent manner (Mejia-Toiber et al., 2010).  This cell line when transplanted into 
the inferior colliculus increases the latency for audiogenic seizures (Ross, et al., 2002); it 
increases the latency for tonic-clonic seizures induced by kainic acid, and decreases their 
severity when transplanted into the SNr (Castillo et al., 2006) (Table 2). In a more recent 
  
www.intechopen.com
 
The Role of Cell Therapy in the Treatment of Epilepsy: Lessons from Animal Models 
 
69 
Cell type Model Site of 
transplant 
Behavioral effects 
Histological findings 
Reference 
M213-2O CL-4 Audiogenic 
seizures. 
Inferior 
colliculus 
Inccreases latency to 
audiogenic seizures. 
Ross  
et al., 2002 
M213-2O CL-4 KA-induced SE; 
transplanted 8 
weeks before. 
Substantia 
nigra 
reticulata 
Increases latency for 
tonic-clonic seizures, 
reduces their intensity. 
Castillo  
et al., 2006 
M213-2O CL-4 KA-induced 
SRMS; evaluated 
at 4 and 12 weeks 
after 
transplantation. 
Substantia 
nigra 
reticulata 
Reduces the percentage 
of animals showing 
SRMS; longer survival 
times for transplanted 
rats, GABA content 
increased in area of graft.
Castillo  
et al., 2008 
M213-2O CL-4 Kindling model; 
evaluated for 8 
weeks. 
Substantia 
nigra 
reticulata 
No improvement; strong 
tissue reaction in 
kindled animals. 
Nolte  
et al.,  2008 
M213-2O CL-4 Genetic model of 
absence seizures 
(GAERS) 
Substantia 
nigra 
reticulata 
No reduction in seizures. Castillo  
et al., 2010 
Cortical cell 
line CN1.4 
with 
GAD65cDNA  
Transplanted, 
then kindled in 
amygdala 
Piriform 
cortex 
Increases in pre-kindling 
partial seizure threshold, 
and increased latency to 
the first generalized 
seizure during kindling. 
GAD65 long-term 
expression. 
Gernert  
et al., 2002 
Cortical cell 
line CN1.4 
with 
GAD65cDNA  
Pilocarpine-
induced SE, then 
transplanted, 
evaluated 3 days 
and 7-8 days after 
surgery 
Substantia 
nigra 
reticulata 
Fewer SRMS, integration 
into the host, effect 
diminished if transgene 
is suppressed. 
Thompson & 
Suchomelova, 
2004 
Cortical cell 
line CN1.4 
with 
GAD65cDNA  
Transplanted, 
then hippocampal 
stimulation; 
transplanted, then 
kindling in 
entorhinal cortex 
Dentate 
gyrus 
Increased after discharge 
threshold; longer latency 
to first generalized 
seizure. 
Thompson, 
2005 
GDNF cells 
encapsulated 
in semi-
permeable 
membrane 
Kindling, then 
implanted, then 
rekindled 4 weeks 
later. 
Ventral 
hippcampus
Lower levels of GDNF 
reduced duration of 
afterdischarges, and 
seizure severity. 
Kanter-
Schlifke  
et al., 2009 
GAD: glutamate decarboxylase, the synthetic enzyme for the neurotransmitter GABA; GAERS: Genetic 
Absence Epilepsy Rat from Strasbourg; GDNF: glial derived neurotrophic factor; KA: kainic acid; 
SRMS: spontaneous recurrent motor seizures. 
Table 2. Studies using cell lines in animal models of epilepsy. 
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study, it was found that intranigral transplants of this GABAergic cell line decrease the 
percentage of rats showing spontaneous seizures induced by kainic acid, at 4 and 12 weeks 
after transplantation into the SNr (Castillo et al., 2008) (Table 2).  Beneficial effects are not 
observed in all animal models using nigral transplants of cell line M213-2O CL-4.  In Wistar 
rats in a model of kindling a strong immune reaction was observed (Nolte et al., 2008). This 
strong immune reaction was only observed in kindled animals transplanted with cell line 
M213-CL-4.  In another study, transplants of this cell line did not reduce absence seizures in 
the genetic epilepsy model of the Strasbourg rats (GAERS) (Castillo et al., 2010).   
A different cell line, CN 1.4, contains GAD65 cDNA the other enzyme involved in the 
synthesis of GABA.  The vector used to generate this cell line, produces two gene products, 
a tetracycline-responsive transactivator (tTA) and neomycin phosphotransferase (Thompson 
et al., 2000), thus, when doxycycline is present tTA cannot bind to the promoter, and cannot 
direct transcription (Thompson 2005).  Transplants of this cell line into the SNr reduce 
susceptibility to crisis in the model of kindling and reduce the number of epileptiform 
spikes in lithium pilocarpine-induced seizures (Gernert et al., 2002; Thompson & 
Suchomelova, 2004) (Table 1). In the entorhinal cortex-kindling model Thomspon (2005) 
observed increased GABA levels in the hippocampus 3 and 10 days after transplantation of 
this cell line. They found that behavioral seizures and afterdischarges were reduced only in 
the animals with transplants of the GABA cells. GABA levels in vivo and in vitro decreased 
when the cells were treated with doxycycline, and so did the behavioral effects.  
In a recent study a genetically modified cell line that synthesizes and releases the glial 
derived neurotrophic factor (GDNF) was encapsulated in a semipermeable membrane and 
transplanted into the hippocampus.  Those animals transplanted with capsules that released 
a moderate amount of GDNF showed a decrease in the severity of the seizures and in the 
duration of the afterdischarge (Kanter-Schlifke, et al., 2009). 
 At present, there are no other cell lines that have been tested in animal models of epilepsy.  
These studies taken together, have demonstrated that increasing levels of the inhibitory 
transmitter GABA into the SNr, hippocampus, amygdala, piriform cortex, or inferior 
colliculus, does reduce seizures in a variety of animal models.  The challenge is to take this 
knowledge and transform it into a therapeutic strategy that may be successful in the clinical 
setting. 
4. Clinical studies using cell transplants: lessons from Parkinson’s disease 
Preclinical proof-of-concept studies are necessary to show that transplanted cells can 
survive, differentiate, integrate, and exert functional effects in the animal model of choice.  
They are also necessary to find the shortcomings and undesirable side effects of these 
procedures.  However, animal models can only go so far in providing information about the 
use of neural transplants in the clinical setting.  These experimental models have evident 
shortcomings because they cannot reproduce the particular environment of the diseased 
brain, the progression of the illness, or the survival time of the host, among others.  In this 
sense, only clinical studies can definitively answer the question of whether or not 
transplants can reduce the symptoms or slow the progression of the disease, and for how 
long they may give the patient an overall better quality of life. 
The clinical studies using neural and adrenal transplants in Parkinson’s disease (PD), can 
provide with a wealth of information regarding the potential of this procedure, its 
shortcomings, and the factors that still need to be resolved.  PD is a progressive neurological 
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disorder characterized by tremor, rigidity, and slowness of movements, associated with cell 
loss in the substantia nigra, pars compacta, and other brain structures (Tolosa et al., 2006).  
Substantia nigra pars compacta cells (SNc) produce and release dopamine (DA) in the 
caudate nucleus and putamen, a neurotransmitter involved in motor behavior.  In addition 
to loss of DA cells in the nigra, other histopahtological signs include the presence of 
dystrophic neurites, and Lewy body inclusions in the surviving DA cells.  Lewy bodies are 
α-synuclein and ubiquitin-containing intracytoplasmic inclusions (Kövari et al., 2009).  PD 
was the first neurological disorder in which neural transplants were used.  The source of 
tissue for transplantation initially were adrenal medulla chromaffin cells, since they produce 
and release substantial quantities of catecholamines (Drucker-Colin & Verdugo-Diaz, 2004).  
In 1990, Freed et al., wrote a thorough review about the status of intracerebral adrenal 
medulla grafts, they reviewed the results of about ten of the early studies of adrenal grafts 
for the treatment of Parkinson’s disease. Two primary methods of autotransplantation were 
used then, the first involved transplantation of adrenal medulla into the striatum by 
stereotaxic injection; the other involved transplantation of the adrenal tissue to cavities in 
the wall of the lateral ventricle.  The conclusions of this review indicated that intrastriatal 
adrenal medulla grafts caused only a transient improvement, whereas intraventricular 
grafts appeared to have a more lasting effect.  The degree of improvement, though, differed 
among studies, and ranged from substantial to modest.  The major improvements had to do 
with increases in duration of “on” times, that is the time when the medication is having an 
effect, and the patient can move.  In Parkinson’s disease there are fluctuations in the 
response to the medication, this periods are known as “on”, and “off”.  Great variability was 
observed from patient to patient, the majority   improved only slightly and a few had 
greater effects. The evidence also suggested that the creation of a cavity on the wall of the 
ventricle could enhance the trophic effects of the grafts. In this review, the authors 
advocated the use of quantitative objective measures of motor function, in addition to rating 
scales only; the inclusion of control trials involving comparisons between patients receiving 
grafts and controls, non-treated groups, or groups receiving other treatments. They 
concluded that when adrenal medulla grafts survive the functional effects could be the 
result of release of dopamine, and possibly other substances. When they do not survive, the 
functional effects must be attributed to the host brain reaction to injury or to the release of 
chemical substances with trophic effects outlasting their production, or the production of 
substances by surviving non-chromaffin cells.  At that time, postmortem studies in human 
patients showed lack of tyrosine hydroxylase (TH) positive cells (tyrosine hydroxylase is the 
rate-limiting enzyme in the synthesis of dopamine and norepinephrine) but there was not 
enough data to correlate the clinical outcome to the presence or absence of TH positive cells. 
In a later review of the field, Freed (1993) addressed the results of fetal mesencephalic 
transplants in human patients with Parkinson’s disease.  These studies reported clinical 
improvement over the course of several months after transplantation.  Early changes were, 
according to the author, qualitatively similar to those observed after adrenal grafts. Positron 
emission tomography (PET) studies indicated increased 6-[18F]-fluoro-L-dopa (FD) uptake in 
the region of the graft.  FD is a marker that allows monitoring of the uptake and 
decarboxylation of FD to fluorodopamine (FDA), and the subsequent storage of FDA in 
synaptic vesicles, thus giving an indication of pre-synaptic DA function (Au et al., 2005). At 
that time, no controlled studies on mesencephalic grafts had taken place.   A decade later, 
Roitberg et al. (2000) reviewed the clinical studies using neural grafting for Parkinson’s and 
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Huntington’s disease. At that time more than 150 procedures for fetal transplantation in 
Parkinson’s disease had been reported over the world.  The range of clinical benefits was 
variable, some patients showed improvement in terms of reductions in “off” periods, 
reduction of medication, increase in FD uptake in the grafted areas, improvement in 
activities of daily living scores, while others showed no improvement, and some patients 
developed dyskinesia contralateral to the implanted side. Some degree of clinical 
improvement had been observed even 60 months after transplantation. In terms of 
anatomical characteristics, the authors indicated that TH positive neurons were identified in 
the graft of a patient that died 18 months postoperatively from an event unrelated to the 
surgery. Electron microscopic studies indicated synapses between transplanted TH cells and 
host cells in the putamen.   
Several technical improvements were made in the decade between 1990 and 2000 that could 
account for better outcome of grafting procedures. Among them were a more favorable 
donor age, considered to be when dopaminergic cells first appear in the subventricular zone 
just prior to neuritic process extension.  Grafts of fetal tissue older than 9 weeks gestational 
age did not show significant clinical effects or survival of TH positive cells.  Another issue 
was time between obtaining the tissue and grafting, studies showing clinical benefits used 
tissue within 24-48 h of tissue acquisition (Roitberg et al., 2000). An advantage of solid 
versus suspension grafts was suggested, and the number of transplanted cells was also 
important.  Apparently the greater the number of replacement cells, the better the clinical 
effect.  Another factor was the location of the transplant, whether caudate nucleus or 
putamen, Roitberg et al., (2000) suggested that the putamen was a better site for 
implantation, and that greater improvement could be achieved by bilateral transplants.  
Importantly, transplants of TH+ cells had been shown to extend neuritic processes up to 5-7 
mm from the grafted site, although complete reversal of symptoms had not been achieved in 
spite of this innervation pattern. The need for immunosuppression had not been firmly 
established. 
In the first decade of this century, the results of two double-blind controlled trials were 
published. The first in 2001 by Freed et al., reported on the results of operations on 40 
patients that began in 1995 and ended in 1998, and included a sham group, that later had the 
option of receiving the graft.  The results of the study were rather sobering, motor aspects 
improved 18% in the transplanted group as a whole, and 34%, if only patients 60 years of 
age or younger were considered.  Rigidity and bradykinesia were reduced in the younger 
groups, but no improvement on tremor was observed. FD indicated an increase in 
radionuclide uptake in the putamen of the transplanted group, without changes in the sham 
group.  One 66-year-old patient died of causes unrelated to the surgical procedure seven 
months after transplantation, and the postmortem analysis of the brain indicated the 
presence of TH+ cells with outgrowth of 2-3 mm, without Lewy bodies. Postmortem 
analysis of the brain of another patient (a 68-year-old man who died three years after the 
transplantation procedure, also from causes unrelated to the surgery) showed surviving 
dopamine cells in the tissue, with outgrowth that extended the full width of the putamen. 
PET-FD had shown 100% improvement in uptake over baseline measures. On a three-year 
follow-up, there was a 38% improvement in the younger group of patients and 14% of older 
patients, five patients developed dystonia and dyskinesia.  The authors concluded that their 
results were similar to those of open studies.  In 2003 the results of another double-blind 
controlled study were reported (Olanow et al., 2003) with similar results. Comparisons 
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between placebo and transplanted groups were not significant even though striatal FD 
uptake was significantly increased in the transplanted groups, and survival of dopamine 
neurons was observed at postmortem examination of five patients who died during the 
study from causes unrelated to the transplant.  Number of surviving TH+ cells ranged from 
30,000-120,000 per side depending if the patient had received a one-donor or a four-donor 
graft.  Activated microglia and immune reactivity was observed in the transplanted group 
in and around the region of the graft.  In addition 56% of transplanted patients developed 
dyskinesia.  The authors concluded that fetal nigral transplantation was not recommended 
at that time.  Goetz et al. (2005) reached a similar conclusion after an evidence-based medical 
review update on the various treatments for PD from 2001-2004.  On the basis of their 
analyses, the authors concluded that fetal mesencephalic grafts were non-efficacious 
meaning that evidence showed that the intervention did not have a positive side effect on 
studied outcomes.   
In 2005 Piccini et al., addressed some of the issues pertaining to the clinical outcome after 
neural transplantation in PD. On the basis of their results with nine patients from a full 
series of fourteen grafted PD patients, they suggested that clinical outcome is best when 
more than 100,000 DA neurons are grafted and at least 1/3 to 1/2 of the putamen is 
reinnervated. This degree of innervation corresponds to 50% of normal FD uptake, although 
as indicated in the previous studies it does not always match with the level of clinical 
improvement.  This study contributed importantly to the discussion of the mechanisms that 
underlie the development of dyskinesia, they found no association between graft-induced 
dyskinesia and DA release under basal or methamphetamine administration.  They also 
concluded that grafts in the putamen do not protect intrinsic DA neurons in the nigra from 
degenerating, that a better outcome can be found in patients in whom the degeneration of 
the intrinsic DA system was confined to areas reached by the graft, and that 
immunosuppression could be stopped without compromising the survival of the grafts or 
the clinical improvement.  From these studies it became clear that the response to the grafts 
varies between individuals, that factors such as tissue handling and storage, 
immunosupressive treatment, and patient selection needs to be improved, thus this type of 
therapy requires that it be tailored individually to each patient (Winkler et al., 2008). 
In a follow-up to the study published by Freed et al. in 2001, Ma et al. (2009) reported the 
results obtained two and four years after transplantation.  Interestingly the motor scores of 
the transplanted patients improved 25% in the 4-year evaluation in the group as a whole. In 
addition, differences found previously between younger and older patients, and men and 
women did not persist over time.  Increased FD uptake was found in both hemispheres, and 
it was correlated to clinical outcome.  They also observed that better outcome was associated 
with the degree of FD uptake present preoperatively in the ventrorostral putamen.  In the 
same region they detected progressive loss over the 4-year period, suggesting ongoing 
neurodegeneration.  
Recently, various studies have addressed the issue of the presence of Lewy bodies, and 
activated microglia in the grafts of patients that received transplants a decade or more 
before (Li et al., 2008; Kordower et al., 2008a, 2008b).  In these studies it was suggested 
that the presence of Lewy bodies could indicate that the microenvironment of the host 
brain may affect DA neurons, or that somehow the pathological process can spread to the 
grafted cells, although the presence of Lewy bodies may not affect the functional effects of 
the grafts.  Importantly, these studies also found survival of TH+ cells in the transplants.  
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In contrast, Mendez et al. (2008) after evaluating the histopathological characteristics of 3-
4, and 9-14 year-old transplants did not find Lewy bodies in the grafts.  In this study, they 
reported that serotonin cells were present, and they suggested that the presence of this 
type of cell could be involved in the development of dyskinesia. Cooper et al., (2009) 
evaluated the histological evidence of the studies dealing with post-mortem cases of 
patients with neural transplants, and concluded that the presence of Lewy bodies could 
be related to the type of graft, solid tissue versus cell suspension, the former having 
resulted in greater microglial activation indicating an increased host inflammatory 
response that could have contributed to the development of PD-like pathology, and to 
accelerated aging in some transplants in PD patients.  In the view of Cooper et al. (2009) 
the vast majority of transplanted neurons in the studies reviewed, remained healthy and 
continued to provide substantial clinical benefits for over a decade. They suggest that 
future studies should look into the use of pluripotent stem (iPS) cells as a source for donor 
cells.  This technology could improve transplant quality and content, by providing sorted 
pure DA populations.  A similar proposal has been expressed in other reviews on the 
future of cell and gene therapies for PD (Isacson & Kordower, 2008; Wang et al., 2007; Li 
et al., 2007; Winkler et al., 2005).   
In conclusion, the review of the studies of neural transplants in PD shows that this therapy 
has to be tailored to each patient, that issues such as the transplantation procedure, i.e., solid 
tissue grafts versus cell suspension grafts, location of the grafts, tissue handling and storage, 
age of donor, immunosuppression therapy, and patient selection in terms of age, gender, 
and degree of degeneration as evaluated by PET-FD uptake have to be taken into 
consideration.  They have also shown that fetal grafts can survive for extended periods, and 
can improve the clinical status of some of the patients for a considerable length of time.  
However, it does not appear to be a therapeutic alternative suited for the majority of PD 
patients. The experience obtained in this regard, needs to be taken into consideration before 
proceeding to the use of cell transplants in epilepsy. Animal studies using models of 
epilepsy have provided valuable information about the functional effects of transplants 
however, a drawback of these studies is the duration of the effects; therefore alternatives 
such as the use of gene therapy are now being considered (Löscher et al., 2008).  
5. Closing remarks 
Advances in molecular and cell biology have now made it possible to immortalize neural 
cells, including stem cells, to replace lost cells or replenish the supply of selected molecules 
(Mejia-Toiber, in press) and have thus provided a new source for neural transplantation, one 
that could possibly be tailored to each patient.  Although unquestionably promising and 
exciting, there are still some issues to be solved before these cells can be used routinely in 
the clinic.  Several authors have voiced concerns similar to those expressed for transplants 
using fetal tissue (e.g., Allan et al., 2010; Kim et al., 2004; Li et al., 2008; Lindvall et al., 2004; 
Muller et al., 2006; Snyder et al., 2004; Storch et al., 2004).  We have classified these concerns 
in two categories. The first one includes the negative effects of transplantation of stem cells 
into the brain.  These include the immune rejection of the transplant, and the effects of 
prolonged immunosuppression. Other negative effects are the potential for tumor formation 
after differentiated ES are transplanted resulting either from residual proliferating ES cells 
or precursors, or by the epigenetic changes resulting from their manipulation and the 
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presence of retroviral vectors. In the case of cell transplantation in PD there is also the 
concern for graft-induced dyskinesia (Allan et al., 2010).  
The second category of concerns includes the need to tailor cell therapy to the pathology of 
interest.  It must be considered if it would be preferable to transplant a homogeneous 
population, for example, neural cells, versus transplanting a mixed population including 
cells of glial lineage in order to favor their integration into the host’s nervous system to 
promote functional recovery.  Stem cells can provide the host environment with trophic and 
neuroprotective support to promote the recovery of endogenous cells, to mobilize host 
progenitors, and to favor inherent neurogenetic programs within the host, in addition to 
replacing host cells (Snyder et al., 2004). Furthermore, the reciprocal stem cell-host 
interaction needs to be taken into consideration, because the host environment may affect 
stem cell behavior by exposing these cells to factors related to the brain pathology of the 
host that may confer an invasive phenotype (Muller et al., 2006).  Indeed, NSC and BMC 
have been shown to migrate to localized and also widespread lesions after transplantation 
(e.g., Costa-Ferro, 2010; Chu et al., 2004); at least three processes seem to influence this 
migratory behavior: inflammation, reactive astrocytosis, and angiogenesis (Muller et al., 
2006).   
Undoubtedly, all these developments from adrenal to fetal grafts, to the generation of NSC 
with specific characteristics have increased our knowledge about the neurologic disorders 
themselves, about the potential for regeneration and restoration of function that the brain 
has, about the effects of neurotrophic factors, and about brain development.  New technical 
alternatives have been found, the use of stem cells, the possibility of induced PSC, and gene 
therapy. One should bear in mind that restoring lost functions by replacing damaged cells is 
not a trivial process if one considers the intricate relationships that exist among nerve cells, 
and that complex neural circuits underlie sensory, motor, and cognitive functions. After 
more than two decades of basic and clinical work in neural transplantation, it has become 
evident that in order to ensure long-term effects neural transplants need to do more than 
just supply the molecule of interest.  However, the positive results obtained in the past 
together with the recent technical advances indicate that in the future we can expect that 
therapeutic alternatives will be available in the clinical setting to improve the quality of life 
of human patients. 
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